• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Meta-Analysis: Does Low Molecular Weight Heparin Reduce the Risk of Preeclampsia in High-Risk Women?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Due to conflicting evidence, Cruz-Lemini et al. (AJOG, 2021) studied the effectiveness of LMWH for the prevention of preeclampsia and other placenta-related complications in high-risk women

METHODS:

  • Systematic review and meta-analysis
  • Data sources
    • PubMed | Cochrane Central Register of Controlled Trials | Abstracts of congresses and scientific meetings | Reference lists of retrieved articles | Published study protocols
    • No publication time restrictions
  • Study inclusion criteria
    • RCTs
    • Studies that compared LMWH or unfractionated heparin (with or without low-dose aspirin) with either placebo or low-dose aspirin (LDA) alone
    • Population: High-risk women, defined as either
      • History of preeclampsia, intrauterine growth restriction, fetal demise, or miscarriage or
      • Screen positive for preeclampsia in the first trimester
  • Study design
    • In addition to overall meta-analysis, subgroup analyses were performed to assess the following
      • Combination LDA and LMWH | LMWH type | Gestational age when treatment was started | Study population particulars (e.g., presence of thrombophilia)
    • Odds ratios (OR) were calculated using a random-effects model
    • Quality of evidence was assessed using GRADE criteria
  • Primary outcome
    • Development of preeclampsia
  • Secondary outcomes
    • Small for gestational age
    • Perinatal death
    • Miscarriage
    • Placental abruption
    • Preterm birth

RESULTS:

  • 15 studies | 2795 participants
  • In high-risk women, treatment with LMWH was associated with reduced odds of
    • Preeclampsia: OR 0.62 (95% CI, 0.43 to 0.90; P=0.010)
    • Small for gestational age: OR 0.61 (95% CI, 0.44 to 0.85; P=0.003)
    • Perinatal death: OR 0.49 (95% CI, 0.25 to 0.94; P=0.030)
  • This reduction in preeclampsia was stronger if LMWH was started <16 weeks
    • OR 0.55 (95% CI, 0.39 to 0.76; P=0.0004)
  • In analyses that included only combined LMWH and LDA, there was a significant reduction in preeclampsia with the combined treatment vs LDA alone
    • OR 0.62 (95% CI, 0.41 to 0.95; P=0.030)
  • Adverse events
    • There was no difference in adverse events between the groups overall, nor when LMWH was combined with LDA
  • Quality of evidence ranged from very low to moderate due to a lack of blinding, imprecision, and inconsistency
  • Type of LMWH
    • Enoxaparin and dalteparin were both associated with a significant reduction in preeclampsia
    • No statistical differences were seen between these medications
  • Secondary outcomes
    • LMWH was associated with reduced risk for SGA
    • LMWH was not associated with reduced risk for other secondary outcomes

CONCLUSION:

  • For high-risk women, LMWH was associated with a reduced risk of preeclampsia and other placental complications
    • Risk reduction was stronger if treatment started <16 weeks
  • A combination of LMWH and low-dose aspirin was associated with a reduced risk of preeclampsia compared to LDA alone
  • The authors suggest 2 potential strategies based on these findings

(1) in a priori low-risk population screened for PE by first-trimester algorithms, prophylaxis with 150 mg of aspirin daily from 12 weeks’ gestation onward

(2) high-risk women based on adverse obstetrical history of placental complications (early-onset PE, SGA, or fetal demise) could benefit from a combined prophylaxis strategy with LMWH plus LDA begun before 16 weeks’ gestation, regardless of the presence of thrombophilia

Learn More – Primary Sources:

Low-molecular-weight heparin for prevention of preeclampsia and other placenta-mediated complications: a systematic review and meta-analysis

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Recurrent Miscarriage and APS: Aspirin and/or Heparin?
Does Enoxaparin Prevent Preeclampsia?
When to Introduce Aspirin to Reduce Risks of Preeclampsia?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site